ADVFN Logo ADVFN

Hot Features

Registration Strip Icon for charts 실시간 차트, 분석 도구 및 가격을 받으려면 등록하세요.

ENTX Entera Bio Ltd

2.00
0.00 (0.00%)
최종 업데이트: 00:45:54
15분 지연
기업명 주식 심볼 시장 주식 타입
Entera Bio Ltd ENTX 나스닥 보통주
  가격 변동 가격 변동 % 주식 가격 최근 거래 시간
0.00 0.00% 2.00 00:45:54
개장가 저가 고가 종가 전일 종가
2.05 1.96 2.12 2.00
시세 정보 더보기 »

최근 뉴스

일자 시간 출처 제목
08/04/202421:30GLOBEEntera Bio Announces Publication of Oral PTH(1-34) Peptide..
26/03/202421:30GLOBEEntera Bio Announces Key Regulatory Milestone for Oral..
20/03/202421:00GLOBEEntera Bio Announces Robust Pharmacokinetic Data for..
09/03/202406:25EDGAR2Form S-8 - Securities to be offered to employees in employee..
09/03/202406:12EDGAR2Form 10-K - Annual report [Section 13 and 15(d), not S-K..
09/03/202406:10EDGAR2Form 8-K - Current report
09/03/202406:05GLOBEEntera Bio Announces Full Year 2023 Financial Results and..
04/03/202422:30EDGAR2Form 8-K - Current report
04/03/202422:30GLOBEEntera Bio Regains Compliance with Nasdaq Minimum Bid Price..
16/02/202407:10EDGAR2Form 424B3 - Prospectus [Rule 424(b)(3)]
15/02/202414:15EDGAR2Form EFFECT - Notice of Effectiveness
14/02/202420:05EDGAR2Form S-3/A - Registration statement under Securities Act of..
03/02/202406:19EDGAR2Form 8-K - Current report
03/02/202406:17EDGAR2Form S-3 - Registration statement under Securities Act of..
30/01/202422:30GLOBEEntera Bio to Present at the Oppenheimer 34th Annual..
16/01/202422:00EDGAR2Form 4 - Statement of changes in beneficial ownership of..
12/01/202408:14EDGAR2Form 4 - Statement of changes in beneficial ownership of..
04/01/202408:59EDGAR2Form 4 - Statement of changes in beneficial ownership of..
04/01/202406:19EDGAR2Form 4 - Statement of changes in beneficial ownership of..
04/01/202406:15EDGAR2Form 4 - Statement of changes in beneficial ownership of..
04/01/202406:11EDGAR2Form 4 - Statement of changes in beneficial ownership of..
03/01/202422:00EDGAR2Form 8-K - Current report
27/12/202322:27EDGAR2Form 4 - Statement of changes in beneficial ownership of..
26/12/202322:00EDGAR2Form 8-K - Current report
26/12/202322:00GLOBEEntera Bio Announces Closing of Private Placement - Extends..
29/11/202322:30GLOBEInterim Results from Ongoing Clinical Study Confirm EB613..
14/11/202321:30GLOBEEntera Bio Reports Q3 2023 Financial Results, Highlights..
10/11/202304:30GLOBEEntera Bio Reports Key Milestone Relating to Oral PTH (1-34)..
16/10/202321:00GLOBEEntera Bio Reports Rapid Pharmacodynamic (PD) Response and..
15/09/202306:03EDGAR2Form 4 - Statement of changes in beneficial ownership of..
15/09/202306:02EDGAR2Form 4 - Statement of changes in beneficial ownership of..
14/09/202305:05EDGAR2Form 8-K - Current report
12/09/202321:30GLOBEEntera Bio Announces Collaboration with OPKO Biologics to..
05/09/202321:00GLOBEEntera Bio to Participate in Upcoming Investor Conferences
24/08/202321:12EDGAR2Form 4 - Statement of changes in beneficial ownership of..
24/08/202321:11EDGAR2Form 3 - Initial statement of beneficial ownership of..
22/08/202322:20EDGAR2Form 4 - Statement of changes in beneficial ownership of..
16/08/202321:30GLOBEEntera Bio to Present Two Abstracts on its First-in-Class,..
16/08/202305:10EDGAR2Form DEF 14A - Other definitive proxy statements
12/08/202305:19EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
12/08/202305:16EDGAR2Form 8-K - Current report
12/08/202305:05GLOBEEntera Bio Announces Q2 2023 Financial Results and Corporate..
01/07/202305:06EDGAR2Form 8-K - Current report
07/06/202320:30GLOBEEntera Bio Adds Sanofi Commercial Leader, Haya Taitel to its..
06/05/202305:05GLOBEEntera Bio Announces Q1 2023 Financial Results and Corporate..
03/05/202322:34GLOBEEntera’s Oral Delivery of GLP-2 Pre-Clinical Data to be..

최근 히스토리

Delayed Upgrade Clock